Table Of Contents:
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By Drug Class Market Trends, Size, and Future Outlook
- By Drug Class Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Drug Class Definitions, Technology Landscape
- By Drug Class Market Drivers
- Product Launches
- Technology Launches
- By Drug Class Market Restraints
- Chapter 4. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By Route of Administration Market Trends, Size, and Future Outlook
- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
- Product Launches
- Technology Launches
- By Route of Administration Market Restraints
- Chapter 5. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- By Distribution Channel Market Restraints
- Chapter 6. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By Disease Indication Market Trends, Size, and Future Outlook
- By Disease Indication Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Disease Indication Definitions, Technology Landscape
- By Disease Indication Market Drivers
- Product Launches
- Technology Launches
- By Disease Indication Market Restraints
- Chapter 7. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By Patient Demographics Market Trends, Size, and Future Outlook
- By Patient Demographics Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Patient Demographics Definitions, Technology Landscape
- By Patient Demographics Market Drivers
- Product Launches
- Technology Launches
- By Patient Demographics Market Restraints
- Chapter 8. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: By End-User Market Trends, Size, and Future Outlook
- By End-User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By End-User Definitions, Technology Landscape
- By End-User Market Drivers
- Product Launches
- Technology Launches
- By End-User Market Restraints
- Chapter 9. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Chapter 10. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market: Competitive Landscape
- Merck & Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AstraZeneca
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Boehringer Ingelheim
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eli Lilly and Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Takeda Pharmaceutical Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bayer AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Janssen Pharmaceuticals, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novo Nordisk A/S
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AbbVie Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Mylan N.V.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Cipla Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Lupin Limited
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co.
- Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
- Appendix
- About Us
Frequently Asked Questions
The current market size of the Dipeptidyl Peptidase IV (DPP-4) Inhibitors industry is USD 10.2 billion.
Rising prevalence of type 2 diabetes, increasing obesity rates, aging global population, sedentary lifestyle trends, development of combination therapies, personalized medicine approach, novel drug delivery systems, and biosimilars & generics.
Side effect concerns, stringent regulatory approvals, high treatment costs, reimbursement challenges, competition from alternative therapies, patent expiries, and pricing pressures.
The sitagliptin segment is the leading component segment in the Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market due to its widespread adoption and cost-effectiveness.
Merck & Co., Novartis AG, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company, Bristol-Myers Squibb, Pfizer Inc., Sanofi, GlaxoSmithKline, Bayer AG, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S, AbbVie Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Limited, and Sun Pharmaceutical Industries Ltd.
The North America region is expected to lead the Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market, with a market share of 35.2% in 2023.
Rising prevalence of type 2 diabetes, increasing obesity rates, aging population, sedentary lifestyle, development of combination therapies, novel drug delivery systems, and favorable reimbursement policies.